MedTrace Logo

Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

NCT05559450 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-09-29

No results posted yet for this study

Summary

To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia

Conditions

Interventions

DRUG

Blinatumomab

Blinatumomab will be bridged to conventional BUCY conditioning regimen.

OTHER

Conventional therapy

Control group will be given conventional BUCY conditioning regimen.

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • Zhongda Hospital

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • The First People's Hospital of Changzhou

    collaborator OTHER

  • Wuxi People's Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wannan Medical College

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Yue Han, MD/PhD · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-01-01
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559450 on ClinicalTrials.gov